CAMBRIDGE, Mass., July 26,
2022 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced that it will host a live conference
call and webcast at 8:00 a.m. ET on Tuesday,
August 2, 2022 to report its second quarter 2022 financial
results and provide a corporate update.
To access the live conference call, please dial 844-200-6205
(domestic) or 929-526-1599 (international), and refer to conference
ID 694684. A webcast of the call will also be available under
"Events and Presentations" in the Investors & Media section of
the Blueprint Medicines website
at http://ir.blueprintmedicines.com/. The archived webcast
will be available on Blueprint Medicines' website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities,
to rapidly and reproducibly translate science into a broad pipeline
of precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-second-quarter-2022-financial-results-on-tuesday-august-2-2022-301592992.html
SOURCE Blueprint Medicines Corporation